14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ALLO vs NBP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NBP Overall Winner
6-Pillar Tally: ALLO 2 – 3 NBP (1 Tie)
Matrix Metrics: ALLO 4 – 5 NBP
As of Nov 16, 2026, NBP (NBP) is the stronger overall head-to-head candidate over Allogene Therapeutics, Inc. (ALLO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). ALLO carries a Unified Composite Score of 42.6/100 (HOLD) at $0.81 (N/M Forward P/E, -4172.6% operating margin), whereas NBP carries 51.9/100 (HOLD) at $0.79 (2.7x Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: ALLO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.4); meanwhile NBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ALLO vs NBP. Trailing 12-month operating profitability (ALLO -4172.6% vs NBP 0.0%) and valuation multiples (ALLO N/M vs NBP 2.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $96.3M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ALLO vs NBP Key Questions & Quantitative Answers
As of Nov 16, 2026, NBP (NBP) is the stronger overall head-to-head candidate over Allogene Therapeutics, Inc. (ALLO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). ALLO carries a Unified Composite Score of 42.6/100 (HOLD) at $0.81 (N/M Forward P/E, -4172.6% operating margin), whereas NBP carries 51.9/100 (HOLD) at $0.79 (2.7x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ALLO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.4); meanwhile NBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ALLO leads the Growth & Scale pillar: ALLO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $4.6M TTM revenue (N/A gross margin, -4172.6% operating margin), compared with NBP at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ALLO generates $4.6M in USD-normalized revenue versus N/A for NBP. In operating R&D and SG&A reinvestment, ALLO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NBP.
NBP screens cheaper on headline valuation multiples. ALLO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 70.1x EV/Revenue (unreported FCF margin), whereas NBP trades at 2.7x Forward P/E, 2.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALLO (-49.3% ROE) versus NBP (-59.1% ROE) capital efficiency.
In options market volatility and institutional positioning, ALLO carries 410.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.84β · 78% Vol realized risk). By comparison, NBP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 80% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.